<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">transplantologiya</journal-id><journal-title-group><journal-title xml:lang="ru">Трансплантология</journal-title><trans-title-group xml:lang="en"><trans-title>Transplantologiya. The Russian Journal of Transplantation</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-0506</issn><issn pub-type="epub">2542-0909</issn><publisher><publisher-name>IPO Association of Transplantologists</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.23873/2074-0506-2025-17-2-157-166</article-id><article-id custom-type="elpub" pub-id-type="custom">transplantologiya-1004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ ТРАНСПЛАНТОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ACTUAL ISSUES OF TRANSPLANTATION</subject></subj-group></article-categories><title-group><article-title>Трансплантация почки и эволюция функции околощитовидных желез: результаты одноцентрового исследования</article-title><trans-title-group xml:lang="en"><trans-title>Kidney transplantation and evolution of parathyroid function: results of a single-center study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1888-8090</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ветчинникова</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Vetchinnikova</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Николаевна Ветчинникова - д-р мед. наук, старший научный сотрудник отделения трансплантации почки</p><p>129110, Москва, ул. Щепкина, д. 61/2</p></bio><bio xml:lang="en"><p>Olga N. Vetchinnikova - Dr. Sci. (Med.), Senior Research Associate, Kidney Transplantation Department</p><p>61/2 Shchepkin St., Moscow 129110</p></bio><email xlink:type="simple">olg-vetchinnikova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ МО МОНИКИ им. М.Ф. Владимирского</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Regional Research and Clinical Institute n.a. M.F. Vladimirskiy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>04</day><month>06</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><fpage>157</fpage><lpage>166</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ветчинникова О.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Ветчинникова О.Н.</copyright-holder><copyright-holder xml:lang="en">Vetchinnikova O.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.jtransplantologiya.ru/jour/article/view/1004">https://www.jtransplantologiya.ru/jour/article/view/1004</self-uri><abstract><sec><title>Введение</title><p>Введение. Функциональное состояние околощитовидных желез (ОЩЖ) у пациентов с хронической болезнью почек (ХБП) до и после трансплантации почки (ТП) тесно взаимосвязаны. Однако дооперационный оптимальный уровень паратиреоидного гормона (ПТГ) крови, препятствующий развитию посттрансплантационного гиперпаратиреоза (ГПТ), остается неизвестным.</p></sec><sec><title>Цель</title><p>Цель. Оценить функциональное состояние ОЩЖ у реципиентов почечного трансплантата на протяжении первого послеоперационного года в зависимости от предтрансплантационного сывороточного уровня ПТГ в целевом диапазоне (150–600 пг/мл).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В ретроспективное когортное одноцентровое исследование включены 157 пациентов с ХБП С5-С5 (Д) с дооперационным уровнем ПТГ крови 150–600 пг/мл, перенесшие первичную ТП и имеющие удовлетворительно функционирующий трансплантат на протяжении года после операции. Определение сывороточных концентраций ПТГ, кальция, скорректированной на альбумин, фосфора и креатинина выполнено стандартными методиками до и после ТП через 3 и 12 месяцев. Целевым уровнем ПТГ крови после ТП считали показатели, не превышающие 130 пг/мл (2-кратное превышение верхней границы референсного интервала, равной 65 пг/мл).</p></sec><sec><title>Результаты</title><p>Результаты. Пациенты были разделены на три группы: первая – 82 пациента с уровнем ПТГ крови 150–300 пг/мл, вторая – 41 с уровнем ПТГ крови 301–450 пг/мл, третья – 34 с уровнем ПТГ крови 451–600 пг/мл. Группы были сопоставимы по соотношению мужчины/женщины, возрасту, первичному почечному заболеванию, модальности и длительности диализа. Через 3 месяца после ТП определялось снижение ПТГ крови у всех больных соответственно в группах до 128 (98;169), 180 (121;222) и 247 (154;299) пг/мл (р&lt;0,001), целевой уровень ПТГ крови определялся соответственно у 58,5%, 34,1% и 20,6% пациентов (р&lt;0,001). К концу года различие в показателях между группами отсутствовало. Регистрировалось снижение фосфора и стабильно нормальный кальций крови. Функция трансплантата на протяжении всего года была одинаковой у пациентов всех групп.</p><p>Установлены прямая тесная корреляция между ПТГ крови до ТП и через три месяца после ТП, менее тесная – через год, слабая взаимосвязь между ПТГ крови и функцией трансплантата через 3 месяца и тесная через год.</p></sec><sec><title>Заключение</title><p>Заключение. Процесс нормализации функции ОЩЖ в ранние сроки после успешной ТП зависит от предоперационного уровня ПТГ крови.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. The functional status of the parathyroid glands (PTG) in patients with chronic kidney disease (CKD) before and after kidney transplantation (KT) is interrelated. The preoperative optimal blood level of parathyroid hormone (PTH) for the prevention of the post-transplant hyperparathyroidism (HPT) development is unknown.</p><p>The objective was to study the function of the PTG after KT during the first postoperative year depending on the pretransplant serum PTH level in the target range (150–600 pg/mL).</p></sec><sec><title>Material and methods</title><p>Material and methods. The retrospective cohort single-center study included 157 patients with preoperative blood PTH levels of 150–600 pg/mL who had undergone primary successful KT for CKD G5-G5(D) at least a year before inclusion in the study. Serum concentrations of PTH, calcium, adjusted for albumin, phosphorus, and creatinine were studied before KT and at 3 and 12 months after it. Blood PTH no more than 130 pg/mL was a target level after KT.</p></sec><sec><title>Results</title><p>Results. Patients were allocated into three groups: 82 patients with blood PTH of 150–300 pg/mL were included into the 1st group; 41 patients with blood PTH of 301–450 pg/mL comprised the 2nd group, and 34 patients with blood PTH of 451–600 pg/mL made the 3rd group. Three months after KT, blood PTH decreased to 128 (98;169) pg/mL, 180 (121;222) pg/mL, and 247 (154;299) pg/mL (p&lt;0.001) in the 1st, 2nd, and 3rd patient groups, respectively; the target blood PTH level was observed in 58.5%, 34.1%, and 20.6% of patients in the respective groups (p&lt;0.001). No differences in the in PTG values were seen between the groups by the end of the year. A decrease in phosphorus and stable normal blood calcium were recorded. The graft function was similar in the patients of all groups throughout the year. A direct close correlation was established between blood PTH before KT and three months after KT, a less close one after one year; the relationship between blood PTH and graft function was weak after three months and a close one after one year.</p></sec><sec><title>Conclusion</title><p>Conclusion. The process of normalization of PTG function in the early stages after successful KT depends on the preoperative blood PTH level.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>трансплантация почки</kwd><kwd>хроническая болезнь почек</kwd><kwd>околощитовидные железы</kwd><kwd>паратиреоидный гормон</kwd><kwd>посттрансплантационный гиперпаратиреоз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>kidney transplantation</kwd><kwd>chronic kidney disease</kwd><kwd>parathyroid glands</kwd><kwd>parathyroid hormone</kwd><kwd>post-transplant hyperparathyroidism</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Messa P, Alfieri C. Secondary and tertiary hyperparathyroidism. Front Horm Res. 2019;51:91–108. PMID: 30641516 https://doi.org/10.1159/000491041</mixed-citation><mixed-citation xml:lang="en">Messa P, Alfieri C. Secondary and tertiary hyperparathyroidism. Front Horm Res. 2019;51:91–108. PMID: 30641516 https://doi.org/10.1159/000491041</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Cianciolo G, Galassi A, Capelli I, Angelini ML, Manna GL, Cozzolino M. Vitamin D in kidney transplant recipients: mechanisms and therapy. Am J Nephrol. 2016;43(6):397–407. PMID: 27229347 https://doi.org/10.1159/000446863</mixed-citation><mixed-citation xml:lang="en">Cianciolo G, Galassi A, Capelli I, Angelini ML, Manna GL, Cozzolino M. Vitamin D in kidney transplant recipients: mechanisms and therapy. Am J Nephrol. 2016;43(6):397–407. PMID: 27229347 https://doi.org/10.1159/000446863</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Padilla PK, Quijano JE, Navarro K, Gonzalez CG. Behavior of bone mineral metabolism in renal posttransplantation patients with severe hyperparathyroidism. Transplant Proc. 2020;52(4):1143–1146. PMID: 32276835 https://doi.org/10.1016/j.transproceed.2020.01.055</mixed-citation><mixed-citation xml:lang="en">Garcia-Padilla PK, Quijano JE, Navarro K, Gonzalez CG. Behavior of bone mineral metabolism in renal posttransplantation patients with severe hyperparathyroidism. Transplant Proc. 2020;52(4):1143–1146. PMID: 32276835 https://doi.org/10.1016/j.transproceed.2020.01.055</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ветчинникова О.Н. Гиперпаратиреоз у кандидатов на трансплантацию почки и функция околощитовидных желез у реципиентов в ранние сроки послеоперационного периода. Вестник трансплантологии и искусственных органов. 2024;26(2):82–93. https://doi.org/10.15825/1995-1191-2024-2-82-93</mixed-citation><mixed-citation xml:lang="en">Vetchinnikova ON. Hyperparathyroidism in kidney transplant candidates and postoperative parathyroid gland function in recipients. Russian Journal of Transplantology and Artificial Organs. 2024;26(2):82–93. (In Russ.). https://doi.org/10.15825/1995-1191-2024-2-82-93</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Okada M, Sato T, Hasegawa Y, Futamura K, Hiramitsu T, Ichimori T, et al. Persistent hyperparathyroidism after preemptive kidney transplantation. Clin Exp Nephrol. 2023;27(10):882– 889. PMID: 37351681 https://doi.org/10.1007/s10157-023-02371-9</mixed-citation><mixed-citation xml:lang="en">Okada M, Sato T, Hasegawa Y, Futamura K, Hiramitsu T, Ichimori T, et al. Persistent hyperparathyroidism after preemptive kidney transplantation. Clin Exp Nephrol. 2023;27(10):882– 889. PMID: 37351681 https://doi.org/10.1007/s10157-023-02371-9</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wang R, Price G, Disharoon M, Stidham G, McLeod MC, McMullin JL, et al. Resolution of secondary hyperparathyroidism after kidney transplantation and the effect on graft survival. Ann Surg. 2023;278(3):366–375. PMID: 37325915 https://doi.org/10.1097/SLA.0000000000005946</mixed-citation><mixed-citation xml:lang="en">Wang R, Price G, Disharoon M, Stidham G, McLeod MC, McMullin JL, et al. Resolution of secondary hyperparathyroidism after kidney transplantation and the effect on graft survival. Ann Surg. 2023;278(3):366–375. PMID: 37325915 https://doi.org/10.1097/SLA.0000000000005946</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Crepeau P, Chen X, Udyavar R, Morris-Wiseman LF, Segev DL, McAdams-DeMarco M, et al. Hyperparathyroidism at 1 year after kidney transplantation is associated with graft loss. Surgery. 2023;173(1):138–145. PMID: 36244806 https://doi.org/10.1016/j.surg.2022.07.031</mixed-citation><mixed-citation xml:lang="en">Crepeau P, Chen X, Udyavar R, Morris-Wiseman LF, Segev DL, McAdams-DeMarco M, et al. Hyperparathyroidism at 1 year after kidney transplantation is associated with graft loss. Surgery. 2023;173(1):138–145. PMID: 36244806 https://doi.org/10.1016/j.surg.2022.07.031</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tsai M-H, Chen M, Liou H-H, Lee T-S, Huang Y-C, Liu P-Y, et al. Impact of pretransplant parathyroidectomy on graft survival: a comparative study of renal transplant patients (2005-2015). Med Sci Monit. 2023;29:e940959. PMID: 37525452 https://doi.org/10.12659/MSM.940959</mixed-citation><mixed-citation xml:lang="en">Tsai M-H, Chen M, Liou H-H, Lee T-S, Huang Y-C, Liu P-Y, et al. Impact of pretransplant parathyroidectomy on graft survival: a comparative study of renal transplant patients (2005-2015). Med Sci Monit. 2023;29:e940959. PMID: 37525452 https://doi.org/10.12659/MSM.940959</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Molinari P, Regalia A, Leoni A, Campise M, Cresseri D, Cicero E, et al. Impact of hyperparathyroidism and its different subtypes on long term graft outcome: a single Transplant Center cohort study. Front Med (Lausanne). 2023;10:1221086. PMID: 37636567 https://doi.org/10.3389/fmed.2023.1221086</mixed-citation><mixed-citation xml:lang="en">Molinari P, Regalia A, Leoni A, Campise M, Cresseri D, Cicero E, et al. Impact of hyperparathyroidism and its different subtypes on long term graft outcome: a single Transplant Center cohort study. Front Med (Lausanne). 2023;10:1221086. PMID: 37636567 https://doi.org/10.3389/fmed.2023.1221086</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Evenepoel P, Jørgensen HS. Skeletal parathyroid hormone hyporesponsiveness: a neglected, but clinically relevant reality in chronic kidney disease. Curr Opin Nephrol Hypertens. 2024;33(4):383– 390. PMID: 38651491 https://doi.org/10.1097/MNH.0000000000000992</mixed-citation><mixed-citation xml:lang="en">Evenepoel P, Jørgensen HS. Skeletal parathyroid hormone hyporesponsiveness: a neglected, but clinically relevant reality in chronic kidney disease. Curr Opin Nephrol Hypertens. 2024;33(4):383– 390. PMID: 38651491 https://doi.org/10.1097/MNH.0000000000000992</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">National kidney foundation. K/ DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl. 3):S1–S201. PMID: 14520607</mixed-citation><mixed-citation xml:lang="en">National kidney foundation. K/ DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl. 3):S1–S201. PMID: 14520607</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int Suppl. 2009;113:S1– S130. PMID: 19644521 https://doi.org/10.1038/ki.2009.188</mixed-citation><mixed-citation xml:lang="en">Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int Suppl. 2009;113:S1– S130. PMID: 19644521 https://doi.org/10.1038/ki.2009.188</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(3):e1. PMID: 30681074 https://doi.org/10.1016/j.kisu.2017.04.001</mixed-citation><mixed-citation xml:lang="en">Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(3):e1. PMID: 30681074 https://doi.org/10.1016/j.kisu.2017.04.001</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Хроническая болезнь почек (ХБП). Клинические рекомендации. Нефрология. 2021;25(5):10–82. Chronic kidney disease (CKD). Clinical recommendations. Nephrology (Saint-Petersburg). 2021;25(5):10–82. (In Russ.). https://doi.org/10.24884/1561-6274-2021-25-5-10-82</mixed-citation><mixed-citation xml:lang="en">Хроническая болезнь почек (ХБП). Клинические рекомендации. Нефрология. 2021;25(5):10–82. Chronic kidney disease (CKD). Clinical recommendations. Nephrology (Saint-Petersburg). 2021;25(5):10–82. (In Russ.). https://doi.org/10.24884/1561-6274-2021-25-5-10-82</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou X, Guo Y, Luo Y. The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients. Renal Failure. 2021;43(1):599–605. PMID: 33781171 https://doi.org/10.1080/0886022X.2021.1903927</mixed-citation><mixed-citation xml:lang="en">Zhou X, Guo Y, Luo Y. The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients. Renal Failure. 2021;43(1):599–605. PMID: 33781171 https://doi.org/10.1080/0886022X.2021.1903927</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016;67:559– 566. PMID: 26321176 https://doi.org/10.1053/j.ajkd.2015.06.023</mixed-citation><mixed-citation xml:lang="en">Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016;67:559– 566. PMID: 26321176 https://doi.org/10.1053/j.ajkd.2015.06.023</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Perrin P, Caillard S, Javier RM, Braun L, Heibel F, Borni-Duval C, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013;13(10):2653– 2663. PMID: 24034142 https://doi.org/10.1111/ajt.12425</mixed-citation><mixed-citation xml:lang="en">Perrin P, Caillard S, Javier RM, Braun L, Heibel F, Borni-Duval C, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013;13(10):2653– 2663. PMID: 24034142 https://doi.org/10.1111/ajt.12425</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bleskestad IH, Bergrem H, Leivestad T, HartmannA, Gøransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014;28(4):479–486. PMID: 25649861 https://doi.org/10.1111/ctr12341</mixed-citation><mixed-citation xml:lang="en">Bleskestad IH, Bergrem H, Leivestad T, HartmannA, Gøransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin Transplant. 2014;28(4):479–486. PMID: 25649861 https://doi.org/10.1111/ctr12341</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Mehrotra S, Sharma RK, Patel MR. Vitamin D, 1,25-Dihydroxyvitamin D, FGF23 and graft function after renal transplantation. Indian J Nephrorgy. 2019;29(4):242–247. PMID: 31423057 https://doi.org/10.4103/ijn.IJN_307_18</mixed-citation><mixed-citation xml:lang="en">Mehrotra S, Sharma RK, Patel MR. Vitamin D, 1,25-Dihydroxyvitamin D, FGF23 and graft function after renal transplantation. Indian J Nephrorgy. 2019;29(4):242–247. PMID: 31423057 https://doi.org/10.4103/ijn.IJN_307_18</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Prasad N, Jaiswal A, Agarwal V, Kumar S, Chaturvedi S, Yadav S, et al. FGF23 is associated with early posttransplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study. Clin Kidney J. 2016;9(5):669–676. PMID: 27679713 https://doi.org/10.1093/ckj/sfw065</mixed-citation><mixed-citation xml:lang="en">Prasad N, Jaiswal A, Agarwal V, Kumar S, Chaturvedi S, Yadav S, et al. FGF23 is associated with early posttransplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study. Clin Kidney J. 2016;9(5):669–676. PMID: 27679713 https://doi.org/10.1093/ckj/sfw065</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Araujo MJCLN, Ramalho JAM, Elias RM, Jorgetti V, Nahas W, Custodio M, et al. Persistent hyperparathyroidism as a risk factor for long-term graft failure: the need to discuss indication for parathyroidectomy. Surgery. 2018;163(5):1144–1150. PMID: 29331397 https://doi.org/10.1016/j.surg.2017.12.010</mixed-citation><mixed-citation xml:lang="en">Araujo MJCLN, Ramalho JAM, Elias RM, Jorgetti V, Nahas W, Custodio M, et al. Persistent hyperparathyroidism as a risk factor for long-term graft failure: the need to discuss indication for parathyroidectomy. Surgery. 2018;163(5):1144–1150. PMID: 29331397 https://doi.org/10.1016/j.surg.2017.12.010</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ma C, Shen C, Tan H, Chen Z, Ding Z, Zhao Y, et al. A novel nomogram for predicting the risk of persistent hyperparathyroidism after kidney transplantation. Endocrine. 2024;86(1):400–408. PMID: 39009921 https://doi.org/10.1007/s12020-024-03963-5</mixed-citation><mixed-citation xml:lang="en">Ma C, Shen C, Tan H, Chen Z, Ding Z, Zhao Y, et al. A novel nomogram for predicting the risk of persistent hyperparathyroidism after kidney transplantation. Endocrine. 2024;86(1):400–408. PMID: 39009921 https://doi.org/10.1007/s12020-024-03963-5</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lou I, Foley D, Odorico SK, Leverson G, Schneider DF, Sippel R, et al. How well does renal transplantation cure hyperparathyroidism. Ann Surg. 2015;262(4):653–659. PMID: 26366545 https://doi.org/10.1097/SLA.0000000000001431</mixed-citation><mixed-citation xml:lang="en">Lou I, Foley D, Odorico SK, Leverson G, Schneider DF, Sippel R, et al. How well does renal transplantation cure hyperparathyroidism. Ann Surg. 2015;262(4):653–659. PMID: 26366545 https://doi.org/10.1097/SLA.0000000000001431</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Montemayor V, Sánchez-Agesta M, Agüera ML, Calle Ò, Navarro MD, Rodríguez A, et al. Influence of pre-kidney transplant secondary hyperparathyroidism on later evolution after renal transplantation. Transplant Proc. 2019;51(2):344–349. PMID: 30879538 https://doi.org/10.1016/j.transproceed.2018.12.012</mixed-citation><mixed-citation xml:lang="en">Garcia-Montemayor V, Sánchez-Agesta M, Agüera ML, Calle Ò, Navarro MD, Rodríguez A, et al. Influence of pre-kidney transplant secondary hyperparathyroidism on later evolution after renal transplantation. Transplant Proc. 2019;51(2):344–349. PMID: 30879538 https://doi.org/10.1016/j.transproceed.2018.12.012</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Perrin P, Kiener C, Javier R-M, Braun L, Cognard N, Gautier-Vargas G, et al. Recent changes in chronic kidney disease-mineral and bone disorders, and associated fractures after kidney transplantation. Transplantation. 2017;101(8):1897–1905. PMID: 27547867 https://doi.org/10.1097/TP.0000000000001449</mixed-citation><mixed-citation xml:lang="en">Perrin P, Kiener C, Javier R-M, Braun L, Cognard N, Gautier-Vargas G, et al. Recent changes in chronic kidney disease-mineral and bone disorders, and associated fractures after kidney transplantation. Transplantation. 2017;101(8):1897–1905. PMID: 27547867 https://doi.org/10.1097/TP.0000000000001449</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Walkenhorst Z, Maskin A, Westphal S, Fingeret AL. Factors associated with persistent post-transplant hyperparathyroidism after index renal transplantation. J Surg Res. 2023;285:229235. PMID: 36709541 https://doi.org/10.1016/j.jss.2022.12.030</mixed-citation><mixed-citation xml:lang="en">Walkenhorst Z, Maskin A, Westphal S, Fingeret AL. Factors associated with persistent post-transplant hyperparathyroidism after index renal transplantation. J Surg Res. 2023;285:229235. PMID: 36709541 https://doi.org/10.1016/j.jss.2022.12.030</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
